Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) will present oncology data at ESMO Congress 2025 in Berlin, Oct 17–21, showcasing results from >50 company‑sponsored, investigator‑sponsored and collaborative studies across >10 cancer types.
Key highlights include first disclosure of a global Phase 1 study of iza‑bren (BL‑B01D1) (EGFR×HER3 ADC) and data that supported an FDA Breakthrough Therapy designation; late‑breaking PFS and first OS from CheckMate‑8HW in MSI‑H/dMMR mCRC; five‑year DFS/OS/ctDNA follow‑up from CheckMate‑274 in high‑risk MIUC; and the nine‑year final analysis of CheckMate‑238 in resected advanced melanoma.
SystImmune (collaborating with BMY) announced the first patient treated in the IZABRIGHT-Breast01 Phase 2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs.
That event triggered a $250 million one-time milestone payment from Bristol Myers Squibb (BMY) under the 2023 collaboration and exclusive license agreement. SystImmune is eligible for up to an additional $250 million near-term and up to $7.1 billion in further contingent development, regulatory and sales milestones. Iza-bren has received Breakthrough Therapy Designation from the FDA for previously treated advanced EGFR-mutated NSCLC and is being evaluated in multiple ongoing global trials.
Bristol Myers Squibb (NYSE: BMY) will acquire Orbital Therapeutics for $1.5 billion cash at closing, adding Orbital’s lead preclinical program OTX-201 and a proprietary RNA platform that combines circular and linear RNA, targeted LNP delivery, and AI-driven design.
The deal aims to expand BMS’s cell therapy portfolio by enabling in vivo CAR T approaches intended to reduce treatment burden and broaden patient access for autoimmune diseases. Closing is subject to customary conditions, including the Hart-Scott-Rodino waiting period, and accounting treatment will be determined at close.
Bristol Myers Squibb (NYSE: BMY) launched COBENFY Connections on October 10, 2025 to reduce stigma around schizophrenia by sharing real stories from adults taking COBENFY™ (xanomeline and trospium chloride), their care partners, and clinicians.
The program, introduced on World Mental Health Day, features TV host Gail Simmons discussing her brother’s lived experience and a hosted gathering that highlighted peer support, treatment exploration, and community connection. The initiative directs audiences to connections.bms.com and includes Important Safety Information for COBENFY.
Bristol Myers Squibb (NYSE: BMY) announced that its anti-MTBR-tau antibody, BMS-986446, has received Fast Track Designation from the FDA for early Alzheimer's disease treatment. The drug, currently in Phase 2 development, targets pathological tau protein fragments and aims to modify the disease's progression by neutralizing tau spread and promoting its clearance.
The investigational therapy has shown promising results in preclinical models, demonstrating significant reductions in tau uptake and spread, and protection against behavioral deficits. A Phase 1 study confirmed safety and tolerability across three dose cohorts. The ongoing Phase 2 study is fully enrolled and will evaluate the drug's impact on disease progression through various biomarkers and clinical outcome measures.
Bristol Myers Squibb (NYSE: BMY) has expanded its direct-to-patient program by introducing the new BMS Patient Connect platform, offering significant discounts on two key medications. Eliquis (apixaban) will be available at over 40% below list price, while Sotyktu (deucravacitinib) will be offered at more than 80% discount starting January 2026.
The initiative aims to improve medication accessibility and affordability across all 50 states and Puerto Rico for eligible cash-paying patients. Sotyktu, a first-in-class TYK2 inhibitor, is used to treat moderate-to-severe plaque psoriasis in adults. The platform will provide patient support resources and may include additional BMS medicines in the future.
Bristol Myers Squibb (NYSE:BMY) announced positive interim results from its Phase 3 EXCALIBER-RRMM study of iberdomide, a novel CELMoD™ therapy, in combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma (RRMM).
The study achieved a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm. The trial will continue to evaluate other endpoints including progression-free survival and overall survival. The safety profile remained consistent with previous studies.
Iberdomide represents the first of a new class of medicines called CELMoDs, potentially establishing a new foundation for multiple myeloma treatment. The company plans to discuss these results with health authorities.
Bristol Myers Squibb (NYSE: BMY) has scheduled its third quarter 2025 financial results announcement for October 30, 2025. The company will host a conference call with the investment community at 8:00 a.m. ET to discuss the results.
Investors and the public can access the live webcast at investor.bms.com, where related materials will be available before the call. A replay will be accessible approximately three hours after the conference concludes on the same platform.
Bristol Myers Squibb (NYSE: BMY) has announced its latest dividend declarations. The company's Board of Directors has declared a quarterly dividend of $0.62 per share on common stock, payable on November 3, 2025, to stockholders of record as of October 3, 2025.
Additionally, the Board declared a quarterly dividend of $0.50 per share on the company's $2.00 convertible preferred stock, which will be payable on December 1, 2025, to stockholders of record as of November 4, 2025.
Bristol Myers Squibb (NYSE:BMY) announced its participation in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum scheduled for September 23, 2025. The company will engage in a fireside chat starting at 9:40 a.m. ET.
Investors and the public can access the session through the company's investor relations website at investor.bms.com. An archived recording will be made available after the event's conclusion.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
